Annual report
4578.TEDINET S100XUA7
Period2025-01-01 → 2025-12-31
Filed2026-03-26
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 149
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.47T | 2025-01-01 → 2025-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.33T | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.02T | 2023-01-01 → 2023-12-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.74T | 2022-01-01 → 2022-12-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.50T | 2021-01-01 → 2021-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥479.4bn | 2025-01-01 → 2025-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥323.6bn | 2024-01-01 → 2024-12-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥468.0bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥335.9bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥142.7bn | 2023-01-01 → 2023-12-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥173.0bn | 2022-01-01 → 2022-12-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥163.6bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥363.1bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥343.1bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥121.6bn | 2023-01-01 → 2023-12-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥133.9bn | 2022-01-01 → 2022-12-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥125.5bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥366.2bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥347.3bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥4.20T | at 2025-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.74T | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.36T | at 2023-12-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥3.10T | at 2022-12-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.82T | at 2021-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.10T | at 2025-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥961.1bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥3.10T | at 2025-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.78T | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.44T | at 2023-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥3.03T | at 2025-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.73T | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.39T | at 2023-12-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥2.23T | at 2022-12-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥2.01T | at 2021-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥534.6bn | at 2025-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥426.2bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥513.3bn | at 2023-12-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥471.6bn | at 2022-12-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥410.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥403.6bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥354.6bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥283.2bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥211.8bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥228.9bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥161.6bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥265.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥190.5bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥81.6bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥95.3bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥137.3bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥189.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥60.3bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥95.5bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥95.8bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥685.06 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥633.76 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥224.1 | 2023-01-01 → 2023-12-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥246.8 | 2022-01-01 → 2022-12-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥231.32 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥246.78 | 2022-01-01 → 2022-12-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥231.15 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥5,743.73 | at 2025-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥5,089.58 | at 2024-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥4,410.8 | at 2023-12-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥4,100.84 | at 2022-12-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,707.64 | at 2021-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 72.3% | at 2025-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.1% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.2% | at 2023-12-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.7% | at 2022-12-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.3% | at 2021-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 12.6% | 2025-01-01 → 2025-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.4% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 5.3% | 2023-01-01 → 2023-12-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.3% | 2022-01-01 → 2022-12-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.5% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 37,758 | at 2025-12-31 | Cons. | Number of employees |
| Employees | 35,338 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 34,388 | at 2023-12-31v | Cons. | Number of employees |
| Employees | 33,482 | at 2022-12-31v | Cons. | Number of employees |
| Employees | 33,226 | at 2021-12-31d | Cons. | Number of employees |
| Revenue | ¥98.8bn | 2025-01-01 → 2025-12-31 | Standalone | Operating revenue1 |
| Revenue | ¥118.0bn | 2024-01-01 → 2024-12-31 | Standalone | Operating revenue1 |
| Revenue | ¥82.4bn | 2023-01-01 → 2023-12-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥57.0bn | 2022-01-01 → 2022-12-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥115.0bn | 2021-01-01 → 2021-12-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥82.7bn | 2025-01-01 → 2025-12-31 | Standalone | Operating income |
| Operating income | ¥102.9bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Ordinary income | ¥84.2bn | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥105.0bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥70.0bn | 2023-01-01 → 2023-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥46.4bn | 2022-01-01 → 2022-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥104.8bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥88.4bn | 2025-01-01 → 2025-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥105.0bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Net income | ¥89.9bn | 2025-01-01 → 2025-12-31 | Standalone | Profit loss |
| Net income | ¥106.4bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥71.0bn | 2023-01-01 → 2023-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥47.4bn | 2022-01-01 → 2022-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥106.0bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.32T | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥1.38T | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥1.21T | at 2023-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.27T | at 2022-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.25T | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥298.8bn | at 2025-12-31 | Standalone | Liabilities |
| Total liabilities | ¥309.6bn | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.03T | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.07T | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.08T | at 2023-12-31v | Standalone | Net assets |
| Net assets / equity | ¥1.06T | at 2022-12-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.07T | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥101.5bn | at 2025-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥130.4bn | at 2024-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥169.52 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥196.52 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥130.92 | 2023-01-01 → 2023-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.37 | 2022-01-01 → 2022-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.5 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥140 | 2025-01-01 → 2025-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥120 | 2024-01-01 → 2024-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥110 | 2023-01-01 → 2023-12-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2022-01-01 → 2022-12-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2021-01-01 → 2021-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,941.14 | at 2025-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,997.67 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,989.83 | at 2023-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,959.51 | at 2022-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,970.44 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 77.4% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.6% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.1% | at 2023-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.6% | at 2022-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.6% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.6% | 2025-01-01 → 2025-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.9% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2023-01-01 → 2023-12-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.4% | 2022-01-01 → 2022-12-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 542,988,917 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 552,024,717 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2023-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2022-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 557,835,617 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 224 | at 2025-12-31 | Standalone | Number of employees |
| Employees | 183 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 151 | at 2023-12-31v | Standalone | Number of employees |
| Employees | 147 | at 2022-12-31v | Standalone | Number of employees |
| Employees | 137 | at 2021-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 61
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-01-01 → 2025-12-31 | ¥9.0bn |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-12-31 | −¥3.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-12-31 | −¥3.6bn |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-12-31 | −¥56.8bn |
| Consumer Productsreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥5.1bn |
| Consumer Productsreportable segment | employees | at 2025-12-31 | 590 pure |
| Consumer Productsreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥34.6bn |
| Consumer Productsreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥34.6bn |
| Consumer Productsreportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥24m |
| Consumer Productsreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥25.1bn |
| Nutraceuticalsreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥38.9bn |
| Nutraceuticalsreportable segment | employees | at 2025-12-31 | 9625 pure |
| Nutraceuticalsreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥577.7bn |
| Nutraceuticalsreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥577.6bn |
| Nutraceuticalsreportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥48m |
| Nutraceuticalsreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥57.7bn |
| Otherreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥17.6bn |
| Otherreportable segment | employees | at 2025-12-31 | 3143 pure |
| Otherreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥115.9bn |
| Otherreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥112.4bn |
| Otherreportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥3.5bn |
| Otherreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥8.0bn |
| Pharmaceuticalsreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥221.7bn |
| Pharmaceuticalsreportable segment | employees | at 2025-12-31 | 22897 pure |
| Pharmaceuticalsreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥1.74T |
| Pharmaceuticalsreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥1.74T |
| Pharmaceuticalsreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥445.3bn |
| —segment total | capex | 2025-01-01 → 2025-12-31 | ¥283.3bn |
| —segment total | employees | at 2025-12-31 | 36255 pure |
| —segment total | revenue | 2025-01-01 → 2025-12-31 | ¥2.47T |
| —segment total | revenue external | 2025-01-01 → 2025-12-31 | ¥2.47T |
| —segment total | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥3.6bn |
| —segment total | segment profit | 2025-01-01 → 2025-12-31 | ¥536.2bn |
| Reconciling Itemsreconciling | capex | 2024-01-01 → 2024-12-31 | ¥9.9bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥3.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥3.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥51.8bn |
| Consumer Productsreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥3.6bn |
| Consumer Productsreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥33.8bn |
| Consumer Productsreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥33.8bn |
| Consumer Productsreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥7m |
| Consumer Productsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥23.0bn |
| Nutraceuticalsreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥54.2bn |
| Nutraceuticalsreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥557.0bn |
| Nutraceuticalsreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥557.0bn |
| Nutraceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥37m |
| Nutraceuticalsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥59.8bn |
| Otherreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥7.7bn |
| Otherreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥113.7bn |
| Otherreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥110.1bn |
| Otherreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥3.6bn |
| Otherreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥7.5bn |
| Pharmaceuticalsreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥252.0bn |
| Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥1.63T |
| Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥1.63T |
| Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥285.1bn |
| —segment total | capex | 2024-01-01 → 2024-12-31 | ¥317.4bn |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥2.33T |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥2.33T |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥3.6bn |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥375.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,288
| Item | Context | Value | Unit |
|---|---|---|---|
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0090 | |
| Number of shares held | CurrentYearInstant | 222591000 | |
| Shareholding ratio | CurrentYearInstant | 0.4214 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 14857500 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 527868800 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 5278688 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 262617 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 542988917 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 5278688 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 14857500 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 14857500 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0274 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 14857500 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 14857500 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0274 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 36969000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 70.0 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row2Member | 36969000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row2Member | 70.0 | |
| Number of male directors and other officers | FilingDateInstant | 12 | |
| Number of female directors and other officers | FilingDateInstant | 5 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.294 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000OtsukaIchiroMember | 7888000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000InoueMakotoMember | 87000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000MatsuoYoshiroMember | 93000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000MakinoYukoMember | 38000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000TakagiShuichiMember | 46000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000KobayashiMasayukiMember | 94000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000TojoNorikoMember | 75000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000HiguchiTatsuoMember | 209000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000MatsutaniYukioMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000AokiYoshihisaMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000MitaMayoMember | 0 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000KitachiTatsuakiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000SeguchiJiroMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000TobaYozoMember | 8000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000SugawaraHiroshiMember | 8000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000OsawaKanakoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E21183-000TsujiSachieMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 8549000 | |
| Audit fees reporting company | Prior1YearDuration | 131000000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | 12000000 | JPY |
| Audit fees reporting company | CurrentYearDuration | 130000000 | JPY |
| Non audit fees reporting company | CurrentYearDuration | 4000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |